On the stock market since 2021, it operates in the world of health and science. It has 86 employees. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $90.6M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $96.6M in the vault; even if every debt were paid off, $90.6M would remain.
Over the last 12 months, company executives reported 26 buys and 6 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $11.33 — 200% above today’s price.
The growth engine is running at low revs right now. Report-card grade: 3/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 48/100.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, SABS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SABS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.